BioVie, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for BIVI, updated each market day.
BIVI AI Sentiment
AI sees no strong directional signal for BioVie, Inc. Common Stock stock over the next 10 market days.
Prediction date: Sept. 22, 2026
Exact scores are in the SharePreds app
The precise prediction score for this stock, with buy and sell targets and a stop loss, updated every market day.
About BioVie, Inc. Common Stock
BioVie Inc is a clinical-stage company developing drug therapies for the treatment of neurological and neurodegenerative disorders and liver disease. Its therapeutic areas include Alzheimer's, Parkinson's, Long COVID, Ascites, Longevity, and Epigenetics. In liver disease, its investigational drug candidate BIV201 (continuous infusion terlipressin) was granted FDA Fast Track status and FDA Orphan Drug designation for ascites due to all etiologies except cancer. BIV201 is being evaluated as a treatment option for patients suffering from life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.
Sector
Exchange
Market Cap
$15,185,443
Cap Tier
Employees
13
Headquarters
CARSON CITY, NV
Listed Since
Jan. 14, 2014
Website
BIVI Sentiment Trend: Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
BIVI Volatility
BioVie, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings: this can present both opportunity and risk for traders.
